Human-based evidence for the therapeutic potential of arginase inhibitors in cardiovascular diseases.
Sign Up to like & getrecommendations! Published in 2020 at "Drug discovery today"
DOI: 10.1016/j.drudis.2020.11.005
Abstract: Arginase is a ubiquitous enzyme that regulates polyamine- and nitric-oxide-requiring vascular functions. It is well-established that, in mammals, arginase overactivation contributes to endothelial dysfunction, a hallmark of cardiovascular diseases. The pharmacological potential of arginase inhibition… read more here.
Keywords: arginase inhibitors; human based; arginase; potential arginase ... See more keywords
Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2
Sign Up to like & getrecommendations! Published in 2022 at "Molecules"
DOI: 10.3390/molecules27165134
Abstract: Arginases are often overexpressed in human diseases, and they are an important target for developing anti-aging and antineoplastic drugs. Arginase type 1 (ARG1) is a cytosolic enzyme, and arginase type 2 (ARG2) is a mitochondrial… read more here.
Keywords: arginase; virtual screening; arginase type; potential arginase ... See more keywords